PURPOSE: Galectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy. EXPERIMENTAL DESIGN: Urine was collected from all types of cancer patients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3. RESULTS: Cancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I-V, respectively, at P approximately <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy. CONCLUSIONS: Sample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.
PURPOSE:Galectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy. EXPERIMENTAL DESIGN: Urine was collected from all types of cancerpatients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3. RESULTS:Cancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I-V, respectively, at P approximately <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy. CONCLUSIONS: Sample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.
Authors: T Shimonishi; K Miyazaki; N Kono; H Sabit; K Tuneyama; K Harada; J Hirabayashi; K Kasai; Y Nakanuma Journal: Hum Pathol Date: 2001-03 Impact factor: 3.466
Authors: E L Kanabrocki; M D Ryan; D Murray; R W Jacobs; J Wang; A Hurder; N C Friedman; G Siegel; B Eladasari; B A Nemchausky; G Cornelissen; F Halberg Journal: Clin Ter Date: 2006 Mar-Apr
Authors: Pratima Nangia-Makker; Victor Hogan; Yuichiro Honjo; Sara Baccarini; Larry Tait; Robert Bresalier; Avraham Raz Journal: J Natl Cancer Inst Date: 2002-12-18 Impact factor: 13.506
Authors: J Herrmann; C W Turck; R E Atchison; M E Huflejt; L Poulter; M A Gitt; A L Burlingame; S H Barondes; H Leffler Journal: J Biol Chem Date: 1993-12-15 Impact factor: 5.157
Authors: Wouter C Meijers; A Rogier van der Velde; Willem P Ruifrok; Nicolas F Schroten; Martin M Dokter; Kevin Damman; Solmaz Assa; Casper F Franssen; Ron T Gansevoort; Wiek H van Gilst; Herman H Silljé; Rudolf A de Boer Journal: J Am Heart Assoc Date: 2014-09-18 Impact factor: 5.501
Authors: Emanuela Anastasi; Silvia Gigli; Maria Santulli; Sara Tartaglione; Laura Ballesio; Maria Grazia Porpora; Teresa Granato; Carlo Catalano; Antonio Angeloni; Lucia Manganaro Journal: Asian Pac J Cancer Prev Date: 2017-05-01